NMRA — Neumora Therapeutics, Inc.
Is NMRA overbought or oversold? Here is the current MarketMoodz read.
Neumora Therapeutics, Inc. (NMRA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.37. The rating moved from Oversold to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.37
- Last changeMoved from Oversold to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Neumora Therapeutics, Inc. (NMRA) is a small, clinical-stage neuroscience company with valuation driven by a few binary clinical and partnering events. Current market dynamics favor larger, defensive pharma and fund flows away from micro‑cap biotech, while the company likely faces limited cash runway and potential dilution without near-term positive readouts or deals. Key upside would come from successful clinical data or an M&A/partnership outcome; primary near-term risks are trial failures, financing-related dilution, and low liquidity which can amplify downside.
Key factors
- Preclinical/clinical-stage neuroscience focus with high binary clinical readouts that will materially move valuation
- Limited visible cash runway and recurring need for external financing in the sector, increasing dilution risk
- Low current trading liquidity and micro‑cap volatility amplify downside on negative news
- Sector flows favor large‑cap pharma and defensive healthcare, reducing investor appetite for small biotech risk
- Potential upside catalysts include positive clinical data, strategic partnerships or acquisition interest from larger pharma
- Regulatory and reimbursement environment for CNS drugs is challenging and outcomes are uncertain
Risks
- Clinical trial failures or delays that would sharply reduce valuation
- Severe dilution from equity raises or convertible debt financings to extend runway
- Regulatory setbacks or unfavorable FDA guidance for CNS indications
- Adverse market-wide risk-off episodes further compressing micro‑cap biotech prices
- Competition from larger pharma and other neuropsychiatric programs with deeper pockets
- Limited public and social visibility; lack of analyst coverage may exacerbate price moves
- Operational risks including management execution, enrollment challenges and manufacturing issues
See today's live rating, score and targets
Members see the live hourly rating for NMRA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.